Elite Trades From Anywhere

$100 Off Your First Year

00
Days
00
Hours
00
Mins
00
Sec
Claim Now
Last Close
38.72
Jul 02 • 04:00PM ET Dollar change+0.43 Percentage change(1.12%)
Jul 01, 8:40 AMRigel Pharmaceuticals names Alison L. Hannah, M.D. Executive VP and Chief Medical Officer effective July 1, 2026
Index
RUT
Market Cap
716.40M
Enterprise Value
615.44M
Income
364.23M
Sales
299.77M
Book/sh
21.64
Cash/sh
7.93
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
174
IPO
Nov 29, 2000
P/E
2.07
Forward P/E
8.64
PEG
-
P/S
2.39
P/B
1.79
P/C
4.88
P/FCF
9.04
EV/EBITDA
4.85
EV/Sales
2.05
Quick Ratio
2.48
Current Ratio
2.62
Debt/Eq
0.11
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
18.72
EPS next Y
4.48
EPS next Q
0.13
EPS this Y
-84.82%
EPS next Y
51.66%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
34.76% 22.06%
EPS Y/Y TTM
854.73%
Sales Y/Y TTM
47.61%
EPS Q/Q
-30.22%
Sales Q/Q
10.28%
Insider Own
3.32%
Insider Trans
-1.44%
Inst Own
93.08%
Inst Trans
-1.34%
ROA
107.04%
ROE
174.08%
ROIC
87.74%
Gross Margin
93.39%
Oper. Margin
41.56%
Profit Margin
121.51%
SMA20
12.60%
SMA50
23.60%
SMA200
13.82%
Trades
Shs Outstand
18.48M
Shs Float
17.89M
52W High
52.24 -25.88%
52W Low
18.24 112.28%
Volatility
4.50% 4.31%
ATR (14)
1.60
RSI (14)
74.41
Beta
1.15
Rel Volume
1.21
Avg Volume
390.68K
Volume
472,720
Perf Week
4.68%
Perf Month
28.98%
Perf Quarter
40.80%
Perf Half Y
-9.60%
Perf YTD
-9.60%
Perf Year
107.61%
Perf 3Y
200.16%
Perf 5Y
-12.20%
Perf 10Y
76.00%
Prev Close
38.29
Price
38.72
Change
1.12%
Date Action Analyst Rating Change Price Target Change
Nov-05-25Upgrade Jefferies Hold → Buy $42
Apr-03-23Resumed Piper Sandler Neutral $2
Jun-09-22Downgrade Citigroup Buy → Neutral
Jun-08-22Downgrade Piper Sandler Overweight → Neutral $7 → $1
Jun-08-22Downgrade Cantor Fitzgerald Overweight → Neutral $6 → $1
Mar-23-22Initiated B. Riley Securities Neutral $4
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Jul-01-26 08:05AM
Jun-16-26 04:01PM
May-27-26 08:05AM
May-21-26 05:17PM
May-14-26 08:05AM
08:05AM Loading…
May-12-26 08:05AM
07:00AM
May-06-26 08:30AM
May-05-26 04:36PM
04:01PM
Apr-28-26 08:05AM
Apr-07-26 08:05AM
Mar-31-26 08:05AM
Mar-04-26 12:02AM
Mar-03-26 06:02PM
05:15PM Loading…
05:15PM
04:18PM
04:01PM
10:00AM
Feb-27-26 08:32AM
Feb-26-26 10:00AM
Feb-25-26 08:05PM
Feb-24-26 10:00AM
09:02AM
08:05AM
Feb-18-26 08:12AM
Feb-16-26 08:59AM
Feb-03-26 08:05AM
Jan-28-26 11:24AM
Jan-16-26 10:26AM
08:55AM Loading…
08:55AM
Jan-12-26 08:05AM
Jan-09-26 08:05AM
Jan-08-26 12:21PM
09:36AM
Jan-07-26 12:31PM
08:45AM
08:05AM
Jan-06-26 10:00AM
05:33AM
Dec-07-25 09:30AM
Dec-05-25 12:00PM
Dec-03-25 04:00PM
09:40AM
Nov-27-25 09:15AM
Nov-26-25 08:05AM
Nov-17-25 01:38PM
08:05AM
Nov-12-25 08:05AM
Nov-06-25 12:20PM
12:00PM
Nov-05-25 12:01AM
Nov-04-25 05:25PM
04:22PM
04:01PM
Nov-03-25 09:05AM
07:57AM
Oct-31-25 01:53PM
Oct-29-25 08:05AM
Oct-15-25 09:40AM
Oct-14-25 09:35AM
Oct-08-25 08:05AM
Oct-03-25 08:05AM
Sep-29-25 07:09PM
10:04AM
09:40AM
Sep-26-25 09:35AM
Sep-25-25 11:26AM
Sep-18-25 11:25AM
Sep-17-25 02:27PM
Sep-11-25 09:48AM
Sep-09-25 12:00PM
Sep-08-25 02:45PM
Sep-05-25 09:09AM
Sep-03-25 02:02PM
Aug-27-25 01:57PM
Aug-26-25 08:05AM
Aug-25-25 02:03PM
10:15AM
09:15AM
Aug-22-25 09:04AM
Aug-20-25 12:45PM
Aug-15-25 09:50AM
Aug-12-25 09:15AM
09:11AM
Aug-08-25 12:20PM
10:00AM
09:15AM
06:09AM
Aug-07-25 02:00PM
09:55AM
09:15AM
Aug-06-25 03:29AM
Aug-05-25 06:10PM
05:04PM
04:01PM
Aug-04-25 10:00AM
Jul-31-25 10:00AM
Jul-30-25 12:10PM
09:55AM
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
PresidentMr. Raul R. Rodriguez
Executive VP & CFOMr. Dean L. Schorno CPA
Executive VPMr. Raymond J. Furey J.D.
Executive VP & Chief Commercial OfficerMr. David A. Santos
Executive VP & Chief Medical OfficerDr. Lisa Rojkjaer M.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ali-Jackson KamilDirectorJun 22 '26Sale35.002,50087,50010,125Jun 24 04:04 PM
Ali-Jackson KamilDirectorJun 22 '26Proposed Sale35.002,50087,500Jun 22 03:12 PM
Schorno Dean LEVP & Chief Financial OfficerJun 01 '26Option Exercise14.833,38150,13979,718Jun 03 06:03 PM
Ali-Jackson KamilDirectorMay 26 '26Sale29.172,50072,92512,625May 28 04:19 PM
Ali-Jackson KamilDirectorMay 26 '26Proposed Sale29.172,50072,925May 26 10:43 AM
MOOS WALTER HDirectorFeb 20 '26Option Exercise24.004,00096,00016,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Sale36.364,000145,44012,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Proposed Sale36.364,000145,440Feb 20 01:52 PM
RODRIGUEZ RAUL RCEO, PresidentJan 26 '26Option Exercise27.4080,0002,192,000285,243Feb 04 04:20 PM
Schorno Dean LEVP & Chief Financial OfficerDec 22 '25Option Exercise21.516,500139,78664,235Dec 29 08:06 PM